Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Belldegrun

Showing results (21-30 of 126) with videos related to

Pageof 13
Sort By:
Cancer Research|July 14, 1998
The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancerJ Naitoh, O Witte, A Belldegrun
Cancer Research|October 15, 1995
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell linesN Borsellino, A Belldegrun, B Bonavida
Seminars in Urologic Oncology|May 17, 2001
Biology of renal cell carcinoma: changing concepts in classification and stagingA J Pantuck, A Zisman, A Belldegrun
The Journal of Urology|January 1, 1988
Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancerA Belldegrun, I Uppenkamp, S A Rosenberg
International Journal of Urology : Official Journal of the Japanese Urological Association|July 10, 2001
Gene and immune therapy for renal cell carcinomaA J Pantuck, A Zisman, A Belldegrun
The Journal of Urology|May 1, 1993
Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistanceJ T Safrit, A Belldegrun, B Bonavida
The Cancer Journal From Scientific American|February 24, 2000
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinomaA Belldegrun, O Shvarts, R A Figlin
Seminars in Urologic Oncology|November 1, 1996
Renal cell carcinoma: basic biology and clinical behaviorJ R Franklin, R Figlin, A Belldegrun
Reviews in Urology|September 21, 2006
Immune and genetic therapies for advanced renal cell carcinomaA Zisman, A J Pantuck, A Belldegrun
The Prostate|August 10, 1999
Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesisP J Frost, A Belldegrun, B Bonavida
Pageof 13

Showing results (21-30 of 126) with videos related to

Sort By:
Pageof 13
Cancer Research|July 14, 1998
The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancerJ Naitoh, O Witte, A Belldegrun
Cancer Research|October 15, 1995
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell linesN Borsellino, A Belldegrun, B Bonavida
Seminars in Urologic Oncology|May 17, 2001
Biology of renal cell carcinoma: changing concepts in classification and stagingA J Pantuck, A Zisman, A Belldegrun
The Journal of Urology|January 1, 1988
Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancerA Belldegrun, I Uppenkamp, S A Rosenberg
International Journal of Urology : Official Journal of the Japanese Urological Association|July 10, 2001
Gene and immune therapy for renal cell carcinomaA J Pantuck, A Zisman, A Belldegrun
The Journal of Urology|May 1, 1993
Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistanceJ T Safrit, A Belldegrun, B Bonavida
The Cancer Journal From Scientific American|February 24, 2000
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinomaA Belldegrun, O Shvarts, R A Figlin
Seminars in Urologic Oncology|November 1, 1996
Renal cell carcinoma: basic biology and clinical behaviorJ R Franklin, R Figlin, A Belldegrun
Reviews in Urology|September 21, 2006
Immune and genetic therapies for advanced renal cell carcinomaA Zisman, A J Pantuck, A Belldegrun
The Prostate|August 10, 1999
Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesisP J Frost, A Belldegrun, B Bonavida
Pageof 13